Skip to main content

Table 8 Abortion occurring in women treated with artemether-lumefantrine

From: Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia

Case

Time of abortion (gestation week)

Time of AL treatment (gestation week)

Reason for AL treatment

Comments

A

13

9

Index episode

Syphilis at Week 10

B

10

6

Index episode

-

C

18

6

Index episode

-

D

15

7

Index episode

Viable embryo at Week 11 on ultrasound

E

27a

6 and 16

Index episode

3 malaria episodes at Weeks 6, 11 (received SP), and 16

F

22

10

Non-index episode

2 previous spontaneous abortions; 3 malaria episodes at Weeks 7 (received SP), 10, and 22 (received SP); at Week 20 severe respiratory tract infection, anaemia, oral candidiasis, and immunosuppression (suspected HIV positive): spontaneous abortion at Week 22, followed by maternal death 24 hours later

Gb

6 days after AL treatment

Between Weeks 6 and 9

Index episode

Treatment with salbutamol for threatened abortion during AL treatment

  1. All cases of abortion occurred in women who received AL during the first trimester; cases A-D, and G received AL only during the pregnancy.
  2. Index episode: falciparum malaria episode that had occurred most recently prior to study enrolment.
  3. AL = artemether-lumefantrine; SP = sulphadoxine-pyrimethamine
  4. a Therapeutic abortion following intrauterine death.
  5. b Incomplete LMP date, therefore, counted as unknown first trimester exposure.
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us